Debate Over Affordable Weight-Loss Drugs and Their Safety
The rise of cheaper, replica weight-loss drugs has challenged major pharmaceutical companies like Novo Nordisk and Eli Lilly, leading to legal and regulatory actions to curb the production of compounded versions that pose health risks, while also highlighting issues of drug affordability and access for patients.